JNJ Latest Headlines

Pfizer (PFE) Stock Looks Attractive for Income Investors

at www.tipranks.com (Thu, 5-Nov 8:32 AM)

Intuitive Surgical Stock (ISRG) Still Looks Worth Its Premium

at www.tipranks.com (Wed, 4-Nov 9:26 AM)

S&P 500 negative beta weight tops dot-com bubble - Evercore

at seekingalpha.com (Tue, 3-Nov 12:37 PM)

How health care is on the ballot in the midterms

at seekingalpha.com (Tue, 3-Nov 12:13 PM)

Most and least shorted mid- to mega-cap healthcare stocks at the end of October

at seekingalpha.com (Tue, 3-Nov 10:00 AM)

Teva to buy U.S. rights to two Samsung Bioepis biosimilars

at seekingalpha.com (Tue, 3-Nov 9:16 AM)

Johnson & Johnson reports 94% success rate in trial of coronary artery device

at seekingalpha.com (Sun, 1-Nov 6:57 PM)

Johnson & Johnson reports lower mortality rates with Impella heart pumps

at seekingalpha.com (Sun, 1-Nov 10:14 AM)

JNJ spotlights 77% response rate for RYBREVANT FASPRO regimen in first-line advanced head and neck cancer

Market Chameleon (Mon, 26-Oct 7:29 AM)

JNJ highlights 100% acute procedural success for VARIPULSE Pro and 82.5% 12-month arrhythmia-free results for investigational OMNYPULSE

Market Chameleon (Thu, 22-Oct 8:30 AM)

JNJ Launches Shockwave C2 Aero Fly, A 2 Hz IVL Catheter Designed to Cut Coronary Treatment Time to 115 Seconds

Market Chameleon (Tue, 20-Oct 8:21 AM)

JNJ Highlights 3-Year TREMFYA Data With Up to 94% Clinical Remission in Crohn’s Disease

Market Chameleon (Tue, 13-Oct 11:18 AM)

Johnson & Johnson sets $1.34 quarterly dividend with November 24 ex-dividend date

Market Chameleon (Tue, 13-Oct 7:08 AM)

FDA Greenlights First-ever Therapy for Warm Autoimmune Hemolytic Anemia – J&J’s IMAAVY Redefines the Treatment Landscape

Market Chameleon (Tue, 25-Aug 7:08 AM)

Johnson & Johnson Signals Strategic Interest in Psychiatric Treatment Innovation with $14.6 Billion Deal

Market Chameleon (Thu, 6-Aug 9:47 AM)